Use of Human Embryonic Stem Cells in the Treatment of Thrombocytopenia: a Case Series

CASE REPORT

Geeta Shroff1

1 Director, Nutech Mediworld, New Delhi, India.

Contact information:

Geeta Shroff.

Address: Nutech Mediworld, H-8, Green Park Extension, New Delhi-110016, India.
Tel: +91 11 26180039.
Fax: +91 11 26560089.

Keywords
Thrombocytopenia; Platelets; Human Embryonic Stem Cells; Immunogenicity.

Abstract

Background: Treatment options such as corticosteroids, immunoglobulins medicines, blood or platelet transfusions, or splenectomy are used for thrombocytopenia patients. In the present study, we reported the safety and efficacy of human embryonic stem cell (hESC) therapy in two patients with thrombocytopenia. The patients were presented with general weakness, and were unable to do their routine work. After the laboratory examinations, it was confirmed that both the patients were suffering from thrombocytopenia having platelet count 0.70m³ and 0.80m³, respectively.

Methods and Findings: hESCs used in the present study were obtained from a single, spare, expendable, pre-implantation stage fertilized ovum taken during natural in vitro fertilization (IVF) and free from immunogenicity. After a single treatment session with hESCs, both patients showed an increase in blood platelet count and improvement in their condition. No adverse events (AEs) were reported.

Conclusions: hESC therapy was found to be safe and effective. The study concluded that hESC therapy improved the condition of patients with thrombocytopenia.

Introduction

Thrombocytopenia is defined as the reduction in blood platelet count below the normal platelet count distribution (1.5m³) [1]. It is the second most common hematological disorder after anemia and equally affects both men and women [2]. The platelets play an important role in blood clotting mechanism. The decrease in the platelet number increases the bleeding and blood loss; and when coupled with other clotting disorders can lead to serious morbidity or death [3].
The main causes of thrombocytopenia include ineffective platelet production by bone marrow, increased destruction of platelets and abnormal distribution of platelets. The abnormal distribution or aggregation of platelets can be seen as a result of splenic diseases such as neoplastic, congestive, infiltrative and infections; hypothermia; and massive transfusions [4]. For the treatment of thrombocytopenia, it is important to understand its etiology. The treatment of thrombocytopenia patients depends on the causes and severity of the disease. Different treatments such as corticosteroids, immunoglobulins, blood or platelet transfusions, or splenectomy are available for thrombocytopenia. Corticosteroids, mostly prednisone used as the first line of therapy for thrombocytopenia increases the platelet count by decreasing the activity of the immune system [2, 5]. The main focus of these treatments is to prevent death and disability due to bleeding. However, the use of corticosteroids leads to various adverse events (AEs) such as moon face, bloating, swelling, weight gain, hair loss, depression, hot flushes, visual problem etc [6, 7]. The search for safer, targeted and specific stimulation of thrombopoiesis has gained the attention of researchers and clinicians towards the molecular regulation of different stem cells [8]. Several studies have reported the use of hematopoietic stem cells for the treatment of thrombocytopenia [9, 10]. Here, in the present study, we report the safety and efficacy of human embryonic stem cell (hESC) therapy in two patients with thrombocytopenia.

Methods
hESCs used in the present study were obtained from a single, spare, expendable, pre-implantation stage fertilized ovum taken during natural in vitro fertilization (IVF) process after getting an informed consent. The cell lines were cultured and maintained as per our patented in-house technology (United States Granted Patent No US 8592, 208, 52) in a Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Tissue Practice (GTP) compliant laboratory. The derivation and characterization of hESCs has been presented previously [11]. The safety and efficacy of these hESCs has been established in various terminal conditions including cerebral palsy (CP), spinal cord injury (SCI) and non-healing wounds [12]. The study was approved by independent Institutional Ethics Committee (IEC). A written and video informed consent was obtained from the patients prior to the start of the treatment.

The treatment plan consists of one treatment session with hESC therapy, following an already established treatment protocol [12]. The patients were injected with 1 mL hESCs daily via an intravenous route (i.v) to help cells reach the injury site (homing area) for repair and regeneration. Bone marrow aspiration and analysis were not performed for these patients, as the underlying condition was serious. Patients were monitored regularly for the occurrence of any antigenic or anaphylactic reaction by the in-house physicians and nurses during the whole therapy.

Case 1
A 26-year-old male was admitted to our facility in August 2015 with complaints of being unable to lift both arms and forearm above shoulder level, difficulty in getting up from sitting position, weakness of the facial muscles, loss of the muscle mass and winging of the scapula. The patient’s clinical history revealed that in June 2012, he was diagnosed with Fascio scapulo humoral dystrophy (FSHD).

The laboratory examination at our facility showed his platelet count as 0.70m$^3$, that confirmed thrombocytopenia. At our facility, the patient underwent hESC therapy. After the treatment, the patient showed a remarkable improvement in all the symptoms. The patient was able to lift both arms and forearms above the shoulder and could get up at his own. The patient also showed a decrease in the facial muscle weakness, loss of the muscle mass and...
winging of the scapula. The platelet count noted in August 2016 was 1.01 m$^3$ following the treatment. The total blood count before and after the therapy are presented in Table 1. A remarkable improvement was observed in the patient while undergoing hESC therapy, which is difficult to achieve with the currently available therapies.

**Table 1. Blood Platelet Count of the Patient Before, During and at the End of Human Embryonic Stem Cell Therapy**

<table>
<thead>
<tr>
<th>Date</th>
<th>PC (m$^3$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td></td>
</tr>
<tr>
<td>14/8/15</td>
<td>0.70</td>
</tr>
<tr>
<td>18/9/15</td>
<td>0.94</td>
</tr>
<tr>
<td>24/9/15</td>
<td>0.84</td>
</tr>
<tr>
<td>30/09/15</td>
<td>0.93</td>
</tr>
<tr>
<td>1/10/15</td>
<td>0.86</td>
</tr>
<tr>
<td>5/10/15</td>
<td>0.88</td>
</tr>
<tr>
<td>8/10/15</td>
<td>0.98</td>
</tr>
<tr>
<td>22/10/15</td>
<td>1.31</td>
</tr>
<tr>
<td>20/11/15</td>
<td>1.55</td>
</tr>
<tr>
<td>2/12/15</td>
<td>1.26</td>
</tr>
<tr>
<td>8/1/16</td>
<td>1.38</td>
</tr>
<tr>
<td>10/1/16</td>
<td>1.59</td>
</tr>
<tr>
<td>3/8/16</td>
<td>1.01</td>
</tr>
<tr>
<td>Case 2</td>
<td></td>
</tr>
<tr>
<td>19/8/15</td>
<td>0.8</td>
</tr>
<tr>
<td>9/9/15</td>
<td>-</td>
</tr>
<tr>
<td>11/10/15</td>
<td>-</td>
</tr>
<tr>
<td>23/10/15</td>
<td>-</td>
</tr>
<tr>
<td>31/10/15</td>
<td>0.73</td>
</tr>
<tr>
<td>4/11/15</td>
<td>1.59</td>
</tr>
<tr>
<td>17/11/15</td>
<td>0.93</td>
</tr>
<tr>
<td>1/12/15</td>
<td>1.12</td>
</tr>
<tr>
<td>26/12/15</td>
<td>1.5</td>
</tr>
<tr>
<td>24/1/16</td>
<td>1.5</td>
</tr>
<tr>
<td>14/3/16</td>
<td>1.05</td>
</tr>
<tr>
<td>26/6/16</td>
<td>1.03</td>
</tr>
</tbody>
</table>

**Case 2**

A 54-year-old female was admitted to our facility in August 2015 with complaints of severe breathlessness, ascites, hepatomegaly, general weakness, inability to do her daily work, cramps in the bilateral legs, and inability to climb stairs. The patient’s clinical history revealed that she was diagnosed with chronic liver disease with portal hypertension in April 2015 subsequent to chronic gastroenteritis in December 2014.

After laboratory examination at our facility, it was confirmed that the patient was suffering from thrombocytopenia having platelet count of 0.80 m$^3$. At our facility, the patient underwent a single treatment session with hESC therapy. After the treatment, the patient showed significant improvement in all the symptoms. The patient was able to do her routine work, showed improvement in cramps in bilateral legs, able to climb the stairs, breath properly, and has started walking without support. The platelet count in June 2016, following the treatment, was estimated as 1.03 m$^3$. The total blood count before and after the therapy are presented in Table 1.

**Discussion**

Thrombocytopenia is a hematological disorder associated with increased destruction, consumption, or decreased platelets production [2]. Currently available treatment options such as corticosteroids, blood or platelet transfusions and immunoglobulins medicines are associated with complications [6, 7]. Recently, the use of stem cell therapy has enhanced the clinical treatment of human patients with thrombocytopenia [13]. Stem cells are being explored by scientists in regenerative medicine for treating various diseases due to their potential to multiply, proliferate and differentiate into any cell type [14, 15]. At the injured site, stem cells produce different trophic factors and reduce the cell loss, promote host regeneration, hence,
restore the function [16]. Lim et al., (1997) described complete remission after autologous stem cell transplantation (ASCT) in patients with refractory idiopathic thrombocytopenia (ITP) [9]. Al-Ahmari et al., (2004) transferred allogenic stem cells into patients with congenital amegakaryocytic thrombocytopenia (CAT). It was observed that allogenic stem cells are safe and effective for the treatment of patients with CAT [17].

The proliferation and differentiating ability of hESCs has made this therapy an attractive therapeutic option. Takayama et al., (2008) reported that hESCs efficiently develop into hematopoietic progenitors and megakaryocytes capable of releasing functional platelets [18].

The present study reported the use of in-house cultured hESC therapy in the treatment of two patients with thrombocytopenia. After hESC therapy at our facility, these patients showed a significant increase in blood platelet count which further helps in improvement of symptoms such as breathing, lethargy, fatigue and ability to do routine work. No AEs were reported. The bone marrow aspiration and analysis was not done as this procedure is painful and often associated with conditions that result in a weakened immune system or low platelet count. A weakened immune system can make the patients more prone to infection, and a low platelet count increases the risk of excessive bleeding [19, 20].

In most of the studies, hESCs have been derived from 8-cell stage fertilized ovum not used clinically [21]. However, hESCs used in present study were obtained from 2-cell staged fertilized spare ovum obtained after a regular IVF procedure. The hESCs derived at this stage are free from immunogenicity [11]. In our previous studies, we have reported the safety and efficacy of hESC therapy in treating various neurological and non-neurological conditions [15, 22, 23].

Studies till now focused on transplantation of embryonic stem cell (ESC) derived primary megakaryocytes, which helps in production of platelets [24, 25]. Human mesenchymal stem cells (hMSCs) produce a variety of hematopoietic cytokines, growth factors, chemokines, such as CXCL12 (SDF-1), Flt-3 ligand (FL), thrombopoietin (TPO), interleukin (IL)-6, IL-11, leukemia inhibitory factor (LIF), macrophage colony stimulating factor (M-CSF), tumor necrosis factor- (TNF-) α, and transforming growth factor-(TGF-) B1, and also express messenger RNA for TPO, a primary regulator for megakaryocytopoiesis and thrombocytopoiesis [26, 27]. These results suggest that MSCs residing within the megakaryocytic microenvironment in bone marrow provide key signals to stimulate megakaryocyte and platelet production [28]. hESCs used in present study might have shown their therapeutic effect by following the same mechanism.

**Conclusion**

The use of hESC therapy in the present study was found to be safe and effective. The patients showed improvement in platelet number. Both patients have not experienced serious AEs during the study as a result of hESC therapy. hESC therapy was well tolerated among both the patients included in the study. No teratoma formation was seen following the treatment. However, clinical studies with large population sizes are needed to gather evidence favoring the use of hESCs in the treatment of thrombocytopenia.

**Acknowledgement**

The author acknowledges all the doctors, staff and patients of the Nutech Mediworld. The author also acknowledges Knowledge Isotopes Pvt. Ltd. (http://www.knowledgeisotopes.com) for the medical writing assistance.

**Funding**

No funding sources were used to sponsor this study.
Competing Interest
The author declares no competing interest associated with the publication of this manuscript.

Abbreviations
AEs: adverse events; CAT: congenital amegakaryocytic thrombocytopenia; CP: cerebral palsy; ESC: embryonic stem cell; FL: Flt-3 ligand; GLP: Good Laboratory Practice; GMP: Good Manufacturing Practice; GTP: Good Tissue Practice; hESC: human embryonic stem cell; hMSC: human mesenchymal stem cell; ITP: idiopathic thrombocytopenia; IVF: in vitro fertilization; IL: interleukin; IEC: Institutional Ethics Committee; i.v: intravenous; LIF: leukemia inhibitory factor; M-CSF: macrophage colony stimulating factor; SCI: spinal cord injury; TPO: thrombopoietin; TNF: tumor necrosis factor

References


